NCT07386444 Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy
| NCT ID | NCT07386444 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Condition | Early Stage Breast Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 58 participants |
| Start Date | 2026-02-16 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 58 participants in total. It began in 2026-02-16 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial studies whether breathing exercises for the muscles that help with breathing air in, inspiratory muscle training (IMT), works to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage breast cancer (BC). Cancer and/or treatments for BC can directly result in muscle wasting that involves breathing muscles, skeletal muscles or heart muscles. Pain, weakness, shortness of breath, and side effects of cancer treatment may lead to lower physical activity levels. IMT involves breathing exercises using a small hand-held device. The device makes it a little harder to breathe in, which may help strengthen breathing muscles. IMT may be an effective way to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage BC.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Within 3 weeks of starting chemotherapy for an early-stage breast cancer diagnosis * Able to exercise independently without needing support * Ability to read, speak, understand English Exclusion Criteria: * Metastatic breast cancer * Unwilling or unable to follow protocol requirements * Any significant health condition which in the investigator's opinion increases the risks of participation or makes the participant unsuitable for the study
Contact & Investigator
The Ohio State University Comprehensive Cancer Center
✉ OSUCCCClinicaltrials@osumc.edu📞 800-293-5066
Dharini M Bhammar, MBBS, PhD
PRINCIPAL INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT07386444 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Early Stage Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07386444 currently recruiting?
Yes, NCT07386444 is actively recruiting participants. Contact the research team at OSUCCCClinicaltrials@osumc.edu for enrollment information.
Where is the NCT07386444 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT07386444 clinical trial?
NCT07386444 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Dharini M Bhammar, MBBS, PhD at Ohio State University Comprehensive Cancer Center. The trial plans to enroll 58 participants.